You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Software as a Service Cardiovascular PACS Based on Web 2.0 Technologies

    SBC: HEART IMAGING TECHNOLOGIES, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Nearly two-thirds of all medical imaging procedures in the United States are performed in physician offices, yet few of these small healthcare providers can afford picture archiving and communication systems (PACS) needed to exchange these images with large hospitals. Without online access to previous imaging tests many procedures are repeated, leading to exces ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Cell therapy of diabetes using broad spectrum multipotent stem cells

    SBC: PLUREON CORP.            Topic: N/A

    DESCRIPTION (provided by applicant): Transplantation of insulin-producing cells in many diabetes patients potentially would restore normal glucose homeostasis and prevent the severe long-term complications of the disease. However, the scarcity of donated pancreata currently limits transplantation of the whole organ or of isolated pancreatic islets to a tiny fraction of those patients who might ben ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Advanced Detection Technologies for Biochips

    SBC: INDEVR, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of the proposed work is the development of innovative detection technologies for biochips (a.k.a. DNA microarrays). It is envisioned that the proposed technologies will enable the application of biochips to biodefense, particularly when a rapid and reliable diagnostic screen is required in the field. The Specific Aims of the proposed wo ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  4. Develop AAV9 gene replacement therapy for treating MPS I

    SBC: NEUROGT INC            Topic: 107

    Project Summary NeuroGT, Inc is a start-up company founded by Dr. Haiyan Fu, an associate professor in the Gene Therapy Center at University of North Carolina at Chapel Hill, with the mission of develop and commercialize effective gene therapy products to treat rare neurogenetic diseases in humans. The goal of this project is to develop an effective gene therapy product targeting the root cause fo ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Development of gene therapy product for treating MPS IIIB

    SBC: NEUROGT INC            Topic: 105

    Project Summary NeuroGT, Inc is a new start-up company founded by Dr. Haiyan Fu, Associate professor in the Gene Therapy Center at University of North Carolina at Chapel Hill, with the mission of develop and commercialize effective gene therapy products to treat rare neurogenetic diseases in humans. The goal of this project is to develop an effective gene therapy product targeting the root cause f ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Novel Class for Opioid Drugs

    SBC: ALGYNOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): The mu-opioid receptor (MOR) is the primary target for opioid analgesics. While opioids are the most frequently used and effective analgesics for the treatment of moderate to severe clinical pain, their prolonged use leads to reduced efficacy and a number of adverse side effects, including post dosing-induced hyperalgesia and analgesic tolerance. MOR induces an ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD

    SBC: MYCOBACTERIA THERAPEUTICS CORPORATION            Topic: NCCIH

    Project Summary Immunoregulation, i.e., balanced expression of regulatory and effector T cells, is thought to be compromised in modern high-income settings due in part to reduced contact with commensal and environmentally derived bacteria, also known as “old friends”. Failed immunoregulation is thought to be one factor contributing to recent increases in stress-related and chronic inflammatory ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Nitric Oxide Microfluidic Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma

    SBC: Irex Pharma LLC            Topic: NIAID

    PROJECT SUMMARY Over 25 million Americans have asthma, which places an economic burden on the U.S. of $81.9 billion. Airway mucus overproduction is a hallmark of asthma, and the quantity and tenacity of mucus are increased during airway exacerbations. Mucolytics degrade mucus, but do not reduce its production. Although corticosteroids and other anti-inflammatory therapies indirectly decrease mucus ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. A novel 3D microscope for imaging and photostimulation

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: NIMH

    DESCRIPTION (provided by applicant): Mental disease, including schizophrenia, depression and autism spectrum disorders, are still poorly understood, although it is clear that they mostly represent cortical disorders. The cortex is the primary site of higher mental functions, and despite extensive research, there is still no unified theory of how the cortex works. This is partl due to the fact that ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government